Irritable bowel syndrome. New treatment drug on the market.
D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D017091:Colitis, Ischemic / Q000139:chemically induced; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D006801:Humans; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*
D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron